Saturday, August 6, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

FDA Accepts BLA for Inhalational Anthrax Countermeasure

by Global Biodefense Staff
June 16, 2015
Biodefense Vaccine Development

Credit: Shutterstock, modified by Global Biodefense

The U.S. Food and Drug Administration (FDA) earlier this month accepted a Biologics License Application (BLA) for an inhalational anthrax countermeasure from Elusys Therapeutics, Inc.

Anthim (obiltoxaximab) is for the treatment and prevention of inhalational anthrax, and is a candidate for future acquisition into the Strategic National Stockpile, the U.S. government’s repository of critical medical supplies for biowarfare preparedness.

Anthim has been developed under Fast-Track status and Orphan Drug Designation by the FDA. The filing acceptance is based on submission of efficacy data studied in animal models of inhalational anthrax and safety data from 350 healthy human volunteers receiving the proposed human therapeutic dose of Anthim administered intravenously.

Efficacy and safety data obtained on intramuscular administration of Anthim were also included in the application. The more common treatment emergent adverse events occurring in clinical trials of Anthim administered by IV infusion compared to placebo included headache, pruritus, cough, urticaria and rash.

“FDA acceptance of our BLA submission is an important milestone toward our goal of supplying Anthim for the Strategic National Stockpile to help protect the U.S. public from the potential deadly bioterror threat of anthrax,” said Elizabeth Posillico, PhD, President and Chief Executive Officer of Elusys.

Anthim is formulated as a solution and is the only anthrax anti-toxin in advanced stages of development that is being investigated for intravenous (IV) treatment and intramuscular (IM) prophylaxis administration. The ability to administer an anti-toxin via IM injection may provide a valuable alternative to IV injection in an emergency where medical resources and personnel may be limited or when IV administration is not feasible.

Anthim has been developed under two contracts with the Biological Advanced Research and Development Authority.

Tags: Animal ModelsAnthraxAntitoxinsBioterrorismStrategic National Stockpile

Related Posts

Influenza Transmission Spikes During Social Gatherings
Medical Countermeasures

New Universal Flu Vaccine Offers Broad Protection Against Influenza A Virus Infections

July 17, 2022
Adverse Events After Simultaneous COVID-19 mRNA Booster, Flu Vaccination
Medical Countermeasures

Adverse Events After Simultaneous COVID-19 mRNA Booster, Flu Vaccination

July 16, 2022
A Treaty to Break the Pandemic Cycle: Don’t Ignore Key Lessons from the Past Two Years
Policy + Initiatives

A Treaty to Break the Pandemic Cycle: Don’t Ignore Key Lessons from the Past Two Years

July 16, 2022
US Starts Clinical Trial for mRNA Nipah Virus Vaccine
Medical Countermeasures

US Starts Clinical Trial for mRNA Nipah Virus Vaccine

July 11, 2022
Load More

Latest News

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

July 27, 2022
Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

July 17, 2022
Influenza Transmission Spikes During Social Gatherings

New Universal Flu Vaccine Offers Broad Protection Against Influenza A Virus Infections

July 17, 2022
Long COVID: National Academies’ Panel Examines Long-Term Health Effects of COVID-19

Long COVID: National Academies’ Panel Examines Long-Term Health Effects of COVID-19

July 17, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy